Cellular Adjuvants for Viral Infection
US-2024299521-A1 · Sep 12, 2024 · US
Conjugates of GM-CSF and IL-7, compositions and methods related thereto
US9375465B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9375465-B2 |
| Application number | US-201214355673-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 13, 2012 |
| Priority date | Nov 14, 2011 |
| Publication date | Jun 28, 2016 |
| Grant date | Jun 28, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
In certain embodiments, this disclosure relates to conjugates comprising GM-CSF and IL-7 and uses related thereto, e.g., enhancing the adaptive immune system. Typically the GM-CSF and IL-7 are connected by a polymer linker, e.g., polypeptide. In certain embodiments, the disclosure relates to nucleic acids encoding these polypeptide conjugates, vectors comprising nucleic acid encoding polypeptide conjugates, and protein expression systems comprising these vectors such as infectious viral particles and host cells comprising such a nucleic acids.
First claim
Opening claim text (preview).
What is claimed: 1. A conjugate comprising a GM-CSF polypeptide and an IL-7 polypeptide, wherein the conjugate comprises the amino acid sequence of SEQ ID NO:1. 2. A pharmaceutical composition comprising the conjugate of claim 1 , and a pharmaceutically acceptable excipient.
Assignees
Inventors
Classifications
Fusion polypeptide · CPC title
IL-7 · CPC title
- A61K39/39Primary
characterised by the immunostimulating additives, e.g. chemical adjuvants · CPC title
Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title
Granulocyte CSF; Granulocyte-macrophage CSF · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9375465B2 cover?
- In certain embodiments, this disclosure relates to conjugates comprising GM-CSF and IL-7 and uses related thereto, e.g., enhancing the adaptive immune system. Typically the GM-CSF and IL-7 are connected by a polymer linker, e.g., polypeptide. In certain embodiments, the disclosure relates to nucleic acids encoding these polypeptide conjugates, vectors comprising nucleic acid encoding polypeptid…
- Who is the assignee on this patent?
- Univ Emory, Childrens Healthcare Atlanta Inc
- What technology area does this patent fall under?
- Primary CPC classification A61K39/39. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jun 28 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).